Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany
Aptivus 250 mg soft capsules.
| Pharmaceutical Form |
|---|
|
Soft capsule. Pink, oblong soft gelatin capsules imprinted with “TPV 250” in black. |
Each soft capsule contains 250 mg tipranavir.
Excipients with known effect: Each soft capsule contains: 100.0 mg ethanol, 455.0 mg macrogolglycerol ricinoleate and 12.6 mg sorbitol
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tipranavir |
Tipranavir is a non-peptidic inhibitor of the HIV-1 protease that inhibits viral replication by preventing the maturation of viral particles. |
| List of Excipients |
|---|
|
Capsule contents: Macrogolglycerol ricinoleate Capsule shell: Gelatin Black printing ink: Propylene glycol |
High density polyethylene (HDPE) bottle with two-piece child-resistant closure (outer and inner shell polypropylene, with a pulpboard/aluminium liner). Each bottle contains 120 soft capsules.
Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany
EU/1/05/315/001
Date of first authorisation: 25 October 2005
Date of latest renewal: 19 June 2015
| Drug | Countries | |
|---|---|---|
| APTIVUS | Austria, Australia, Canada, Estonia, Spain, France, Croatia, Ireland, Lithuania, Poland, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
